Relmada acquires neurosteroid from Asarina

Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being developed as a potential treatment for Tourette's syndrome (TS) and other compulsive disorders.
Relmada acquires new Tourette syndrome treatment asset
CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid,
Relmada Therapeutics acquires Sepranolone from Asarina Pharma
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
CORAL GABLES, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology ...
Psychedelic: Relmada acquires neurosteroid from Asarina
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results
FierceBiotech2d
After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Nasdaq3d
Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for Tourette Syndrome Treatment Development
Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...
RLMD stock touches 52-week low at $0.34 amid sharp annual decline
In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...